Citius Oncology Secures $18 Million to Enhance Growth
Citius Oncology, Inc. (NASDAQ: CTOR) has taken a significant step forward by announcing a concurrent registered direct offering and private placement, aiming to raise $18 million. This bold move is primarily aimed at bolstering the company’s cash position while paving the way for the commercial launch of LYMPHIR™, a groundbreaking immunotherapy designed for the treatment of cutaneous T-cell lymphoma (CTCL).
About the Offering
The funds generated from this offering will be utilized to support the introduction of LYMPHIR into the market. This novel treatment option seeks to improve outcomes for patients suffering from CTCL, making Citius Oncology a notable player in the oncology sector. The initiative was made possible through a definitive agreement with a healthcare-focused investor, who will purchase 1,284,404 shares of common stock at a price of $1.09 per share. In addition to this, the investor will receive unregistered warrants to acquire an equivalent number of shares, which can be exercised five years after receiving stockholder approval.
Details of the Private Placement
In conjunction with the registered direct offering, Citius Oncology has also entered into a private placement for 15,229,358 shares. Each share will be sold at $1.09, mirroring the terms of the direct offering. This grant further solidifies investor confidence in Citius’s strategic direction, with additional warrants included in the placement as well.
Significance of the Funding
H.C. Wainwright & Co. is acting as the exclusive placement agent for these offerings, signaling the seriousness with which Citius Oncology approaches this capital raise. The completion of these transactions is anticipated soon, subject to standard closing conditions, and is expected to greatly enhance Citius’s operational capabilities.
Investor Support and Future Goals
With projected gross proceeds of approximately $18 million, Citius is poised to utilize this funding for the launch of LYMPHIR and for general corporate purposes. Management’s projections suggest that the initial market for LYMPHIR exceeds $400 million, offering Citius Oncology a valuable opportunity within an underserved landscape.
About LYMPHIR and Market Potential
LYMPHIR received FDA approval for adults with relapsed or refractory Stage I–III CTCL and presents a patient-centric treatment alternative. With a growing market for oncology therapies, Citius’s comprehensive approach that features robust intellectual property protections positions it strategically amidst competitive treatment options.
About Citius Oncology, Inc.
Citius Oncology (NASDAQ: CTOR) focuses on pioneering targeted therapies for cancer treatment. The company’s innovative approach, including LYMPHIR, aims to provide alternatives to traditional treatments, thereby addressing unmet medical needs in oncology. Emphasizing a combination of scientific advancement and market demand, Citius Oncology continues to develop solutions that promise improved patient outcomes.
Frequently Asked Questions
What is the purpose of the $18 million raised by Citius Oncology?
The funds will primarily support the commercial launch of LYMPHIR, an innovative cancer immunotherapy.
What is LYMPHIR?
LYMPHIR is a novel treatment approved by the FDA for adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL).
Who is the exclusive placement agent for Citius Oncology's offerings?
H.C. Wainwright & Co. is acting as the exclusive placement agent.
What is the potential market size for LYMPHIR?
The estimated initial market for LYMPHIR is over $400 million, indicating a strong demand for this therapy.
How does the funding enhance Citius Oncology's position?
The funding improves Citius Oncology’s financial stability, enabling them to advance development and commercialization efforts effectively.
